MX2021009520A - Composicion oftalmica para el tratamiento de trastornos visuales. - Google Patents

Composicion oftalmica para el tratamiento de trastornos visuales.

Info

Publication number
MX2021009520A
MX2021009520A MX2021009520A MX2021009520A MX2021009520A MX 2021009520 A MX2021009520 A MX 2021009520A MX 2021009520 A MX2021009520 A MX 2021009520A MX 2021009520 A MX2021009520 A MX 2021009520A MX 2021009520 A MX2021009520 A MX 2021009520A
Authority
MX
Mexico
Prior art keywords
visual disorders
ophthalmic composition
lens
treatment
disease
Prior art date
Application number
MX2021009520A
Other languages
English (en)
Inventor
GALINDO Hugo Sergio GARCÍA
Sarmiento Cynthia Cano
OLMOS Ana Guadalupe CASTILLO
MENDOZA Mizraim MORALES
Original Assignee
Foodvica S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foodvica S A De C V filed Critical Foodvica S A De C V
Priority to MX2021009520A priority Critical patent/MX2021009520A/es
Priority to AU2022323657A priority patent/AU2022323657A1/en
Priority to CA3231154A priority patent/CA3231154A1/en
Priority to PCT/IB2022/057330 priority patent/WO2023012754A1/es
Publication of MX2021009520A publication Critical patent/MX2021009520A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Abstract

Esta invención provee una composición oftálmica para el tratamiento y/o prevención de trastornos visuales provocados por cambios en la estructura del cristalino del ojo, particularmente relacionados con la alteración de las proteínas que lo conforman; la composición oftálmica consiste en un compuesto polifenólico en combinación con un terpenoide, o sus sales o formas cristalinas, en cantidades terapéuticamente efectivas, que requiere bajas dosis de compuestos bioactivos para tratar la enfermedad mediante un número reducido de aplicaciones; en específico, la composición oftálmica de la invención puede emplearse para el tratamiento y reversión de trastornos visuales causados por alteraciones en la estructura del cristalino, tales como las cataratas, al ser capaz de revertir la opacidad del cristalino provocada por la enfermedad.
MX2021009520A 2021-08-06 2021-08-06 Composicion oftalmica para el tratamiento de trastornos visuales. MX2021009520A (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MX2021009520A MX2021009520A (es) 2021-08-06 2021-08-06 Composicion oftalmica para el tratamiento de trastornos visuales.
AU2022323657A AU2022323657A1 (en) 2021-08-06 2022-08-05 Ophthalmic composition for the treatment of visual disorders
CA3231154A CA3231154A1 (en) 2021-08-06 2022-08-05 Ophthalmic composition for the treatment of visual disorders
PCT/IB2022/057330 WO2023012754A1 (es) 2021-08-06 2022-08-05 Composición oftálmica para el tratamiento de trastornos visuales

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2021009520A MX2021009520A (es) 2021-08-06 2021-08-06 Composicion oftalmica para el tratamiento de trastornos visuales.

Publications (1)

Publication Number Publication Date
MX2021009520A true MX2021009520A (es) 2023-02-07

Family

ID=85155533

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009520A MX2021009520A (es) 2021-08-06 2021-08-06 Composicion oftalmica para el tratamiento de trastornos visuales.

Country Status (4)

Country Link
AU (1) AU2022323657A1 (es)
CA (1) CA3231154A1 (es)
MX (1) MX2021009520A (es)
WO (1) WO2023012754A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110212142A1 (en) 2008-11-17 2011-09-01 Laila Pharmaceuticals Pvt.Ltd. Curcuminoids and its metabolites for the application in ocular diseases
KR20170048426A (ko) 2014-08-22 2017-05-08 광저우 캉루이 바이오로지컬 파마슈티컬 테크놀로지 씨오., 엘티디. 시각 장애를 치료하기 위한 조성물 및 방법
WO2017019808A1 (en) 2015-07-27 2017-02-02 Catacore, Inc Compositions for the treatment of cataracts
CN107397745A (zh) * 2016-08-24 2017-11-28 上海毕傲图生物科技有限公司 唑类化合物眼用制剂
CN106344587A (zh) 2016-08-24 2017-01-25 上海毕傲图生物科技有限公司 羊毛甾醇类化合物眼用制剂
CN106511269A (zh) 2016-12-12 2017-03-22 江西中医药大学 一种姜黄素纳米混悬眼用制剂及制备方法
CA3078680A1 (en) 2017-11-17 2019-05-23 Mahmood Piraee Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders

Also Published As

Publication number Publication date
WO2023012754A1 (es) 2023-02-09
AU2022323657A1 (en) 2024-03-21
CA3231154A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
RU2017144173A (ru) Конструкция линзы с центральной зоной лечения с высокой положительной оптической силой и способ предотвращения и/или замедления прогрессирования миопии
MD3439689T2 (ro) Metode de tratament al hiperlipidemiei cu un inhibitor al ANGPTL8 și un inhibitor al ANGPTL3
ZA202109010B (en) Compounds and methods for the treatment of covid-19
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
EA201201465A1 (ru) Лекарственные формы хинонов для лечения офтальмических заболеваний
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
EA201101576A1 (ru) Лекарственная форма токотриенол хинонов для лечения офтальмических (глазных) заболеваний
BR112017026739A2 (pt) compostos para uso no tratamento de distúrbios neuromusculares
MX2018014357A (es) Uso de inhibidores de la via del complemento para tratar enfermedades oculares.
MX360888B (es) Formulaciones oculares para suministro de fármaco al segmento posterior del ojo.
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
BR112012022074A2 (pt) composição compreendendo como ingredientes ativos l-carnitina em combinação com hidroxiquinurenina-o-beta-dl-glicosídeo, para a prevenção e/ou tratamento de patologias dos olhos devido à radiação ultravioleta
MX2016016090A (es) Composicion oftalmica para el tratamiento de infeccion ocular.
PE20220384A1 (es) Composiciones y metodos de oximetazolina para el tratamiento de trastornos oculares
MX2022001069A (es) Composiciones y metodos para el tratamiento de la presbicia.
BR112022000231A2 (pt) Novos métodos
BR112021018591A2 (pt) Compostos e usos dos mesmos
MX2021009520A (es) Composicion oftalmica para el tratamiento de trastornos visuales.
BR112018072127A2 (pt) inibidores de dipeptidil peptidase-4 para o tratamento ocular tópico de doenças neurodegenerativas da retina
EA201290827A1 (ru) Офтальмологический раствор для лечения глазной инфекции, содержащий левофлоксацин или его соль или сольват этих соединений, способ лечения глазной инфекции, левофлоксацин или его соль или сольват этих соединений и их применение
MX2019001421A (es) Composiciones de reelina para el tratamiento de trastornos neurologicos.
MX2020012012A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
BR112023025789A2 (pt) Nitroxolina para uso no tratamento de neurofibroma cutâneo
BR112022018122A2 (pt) Composições e métodos para saúde ocular compreendendo ácidos gordos de cadeia muito longa
WO2017103892A3 (en) Composition for treating and preventing neurological diseases, neuroinflammation, and alzheimer's disease